BioNexus Gene Lab Balance Sheet Health
Financial Health criteria checks 4/6
BioNexus Gene Lab has a total shareholder equity of $9.4M and total debt of $18.6K, which brings its debt-to-equity ratio to 0.2%. Its total assets and total liabilities are $11.0M and $1.6M respectively.
Key information
0.2%
Debt to equity ratio
US$18.56k
Debt
| Interest coverage ratio | n/a |
| Cash | US$4.14m |
| Equity | US$9.39m |
| Total liabilities | US$1.61m |
| Total assets | US$11.00m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: BGLC's short term assets ($7.0M) exceed its short term liabilities ($1.4M).
Long Term Liabilities: BGLC's short term assets ($7.0M) exceed its long term liabilities ($192.0K).
Debt to Equity History and Analysis
Debt Level: BGLC has more cash than its total debt.
Reducing Debt: BGLC's debt to equity ratio has increased from 0% to 0.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BGLC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BGLC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 25.7% each year